Active, not recruitingPhase 2NCT05132166

A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease

Studying Best vitelliform macular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Health Network, Toronto
Intervention
Drug or biologic - anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.(other)
Enrollment
50 target
Eligibility
18 years · All sexes
Timeline
20212026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05132166 on ClinicalTrials.gov

Other trials for Best vitelliform macular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Best vitelliform macular dystrophy

← Back to all trials